Figure 2.

suPAR serum levels do not reflect tumor characteristics. Circulating levels of suPAR are unaltered between NET patients with (A) different tumor localization, (B) with lower or higher Ki-67 rates, (C) histological grade (Grade (G) 1 to 3), (D) functional or nonfunctional disease, (E) SSR positive or negative disease as well SSR positive or negative disease. Furthermore, analysis of different subgroups with. (F) different T-stages, (G) non-metastasized and metastasized patients, (H) lymph node metastases as well as (I) hepatic and (J) peritoneal carcinomatosis did not show any significant difference. (K) postoperative relapse status did not show any significant difference. Box plot are displayed, where the bold line indicates the median per group, the box represents 50% of the values. The horizontal lines show minimum and maximum values of calculated nonoutlier values. NET, neuroendocrine tumors; SSR, Somatostatin receptor.